Omeros Corporation (OMER) Stock Price

OMERStock

$16.20+64.80%52W

Market Cap$1.17B

P/E—

PEG Ratio0.81

Div yield—

Beta3.04

OMER Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)26.92%

Price vs S&P 500 (4W)-11.06%

PEG Ratio0.81

VGM Score64.32

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)3.46x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.95

Price vs S&P 500 (YTD)-17.63%

Gross Margin (TTM)96.40%

Net Profit Margin (TTM)180.34%

EPS (TTM)$1.52

10-Day Avg Trading Volume1.23M

EPS Excl Extra (TTM)$1.52

EPS (Annual)$-2.71

ROI (Annual)8.98%

Gross Margin (Annual)98.78%

Net Profit Margin (5Y Avg)-185.94%

Cash / Share (Quarterly)$1.83

P/E Basic Excl Extra (TTM)9.39x

ROA (Last FY)-56.66%

EBITD / Share (TTM)$-0.72

ROE (5Y Avg)111.99%

Operating Margin (TTM)-50.08%

Cash Flow / Share (Annual)$-1.62

P/B Ratio57.18x

P/B Ratio (Quarterly)16.66x

Net Income / Employee (Annual)$-897,100

EV / Revenue (TTM)37.92x

Net Interest Coverage (TTM)-4.67x

ROA (TTM)46.05%

EV / EBITDA (TTM)7.42x

EPS Incl Extra (Annual)$-2.71

Current Ratio (Annual)2.76x

Quick Ratio (Quarterly)1.88x

3-Month Avg Trading Volume1.86M

52-Week Price Return64.80%

P/E Incl Extra (TTM)9.39x

Revenue / Employee (TTM)$219,600

Tangible BV / Share (Quarterly)$2.03

P/S Ratio (Annual)15.89x

Asset Turnover (Annual)0.41x

52-Week High$21.24

Operating Margin (5Y Avg)-171.04%

EPS Excl Extra (Annual)$-2.71

CapEx CAGR (5Y)-25.33%

26-Week Price Return36.82%

Quick Ratio (Annual)2.67x

13-Week Price Return67.18%

Total Debt / Equity (Annual)5.16x

Current Ratio (Quarterly)1.95x

Enterprise Value$1.46B

Asset Turnover (TTM)0.13x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.72x

Pretax Margin (Annual)-203.39%

Cash / Share (Annual)$2.40

3-Month Return Std Dev83.77%

Gross Margin (5Y Avg)98.25%

Net Income / Employee (TTM)$713,300

ROE (Last FY)55.34%

Net Interest Coverage (Annual)1.30x

EPS Basic Excl Extra (Annual)$-2.71

P/FCF (TTM)1.38x

Receivables Turnover (TTM)0.96x

Total Debt / Equity (Quarterly)21.55x

EPS Incl Extra (TTM)$1.52

Receivables Turnover (Annual)0.00x

ROI (TTM)11.65%

P/S Ratio (TTM)30.52x

Pretax Margin (5Y Avg)-197.82%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.03

Forward P/E22.28x

Price vs S&P 500 (52W)49.27%

P/E Ratio (TTM)9.39x

Year-to-Date Return-5.70%

5-Day Price Return-17.47%

EPS Normalized (Annual)$-2.71

ROA (5Y Avg)-21.95%

Net Profit Margin (Annual)-187.13%

Month-to-Date Return-14.92%

Cash Flow / Share (TTM)$-2.88

EBITD / Share (Annual)$-2.90

Operating Margin (Annual)-168.02%

LT Debt / Equity (Annual)4.04x

ROI (5Y Avg)-36.17%

P/E Excl Extra (TTM)9.39x

LT Debt / Equity (Quarterly)16.70x

EPS Basic Excl Extra (TTM)$1.52

P/TBV (Quarterly)3.46x

P/B Ratio (Annual)1.65x

Inventory Turnover (TTM)0.75x

Pretax Margin (TTM)150.88%

Book Value / Share (Annual)$1.36

Price vs S&P 500 (13W)64.50%

Beta3.04x

P/FCF (Annual)15.78x

Revenue / Share (TTM)$0.43

ROE (TTM)107.50%

52-Week Low$6.24

vGradeC

mGradeB

vgmGradeB

OMER Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.33	$0.10	+128.85%(+$0.43)
Q1 2026	May 13, 2026	-$0.39	$0.57	+244.92%(+$0.96)
Q4 2025	Mar 31, 2026	$2.24	$3.14	+40.18%(+$0.90)
Q3 2025	Nov 13, 2025	-$0.48	-$0.32	+32.98%(+$0.16)
Q2 2025	Aug 14, 2025	-$0.55	-$0.53	+2.51%(+$0.01)

OMER Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OMEROmeros Corporation	C	—	B	30.5x	—	96.4%	—	$16.20
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company developing targeted therapies for complement-mediated diseases and immunologic disorders. The company's lead candidate, narsoplimab, is a monoclonal antibody in clinical trials for rare immune-related conditions including thrombotic microangiopathy following stem cell transplantation and immunoglobulin nephropathy. Omeros also has programs targeting cancer and additional large-market immunologic indications.

OMER Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.02

Revenue estimate$37.27M

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

OMER Insider Transactions

SellSep 23, 2026
BORGES DAVID J.
Officer
Shares: 20,000Value: $419,000
SellAug 31, 2026
CANCELMO PETER B.
General Counsel
Shares: 50,000Value: $929,668
SellAug 27, 2026
HANISH ARNOLD C
Director
Shares: 15,000Value: $282,094
SellAug 24, 2026
BORGES DAVID J.
Officer
Shares: 10,906Value: $206,805
SellAug 20, 2026
CABLE THOMAS J
Director
Shares: 15,000Value: $276,772

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

INBXInhibrx Biosciences, Inc. Common StockBiological Products
EPCEdgewell Personal Care CompanyCosmetics & Toiletries
CRONCronos Group Inc. Common SharePharmaceutical Preparations
TSHATaysha Gene Therapies, Inc. Common StockBiological Products
ECVTEcovyst Inc.Chemicals
ODDODDITY Tech Ltd. Class A Ordinary SharesCosmetics & Toiletries
IMTXImmatics N.V. Ordinary SharesBiological Products
REPLReplimune Group, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.0

Buy

Consensus rating

52-Week Range

Low$6.24

High$21.24